



14425 COLLEGE BLVD STE 130
LENEXA, KS 66215
Phone: (913) 396-8509
(816) 241-3338
(800) 933-6293
Fax: (816) 241-6531
mawdpathology.com

PATHOLOGY LAB
9705 Lenexa Dr
Lenexa, KS 66215

CLINICAL LAB
11070 Strang Line Rd
Lenexa, KS 66215

FOR IMMEDIATE RELEASE
January 30, 2023

Contact: Mary Sabatini
press@mawdpathology.com

MAWD PATHOLOGY TO ADVANCE METHODS FOR CANCER DIAGNOSIS AND TREATMENT WITH SUPPORT FROM LILLY

LENEXA, KS – MAWD Pathology is pleased to announce the launch of a new study designed to examine novel approaches for optimizing molecular tumor profiling using next generation sequencing (NGS) technology in a community-based pathology group setting. The study is in collaboration with the global healthcare leader Eli Lilly and Company.

Significant advances in precision medicine have highlighted the need for accessible and comprehensive molecular testing for all cancer patients. NGS is the gold standard used to determine the unique genomic sequence associated with a patient's tumor. The results can help oncologists develop treatment plans tailored to each patients' specific type of cancer.

In the study, MAWD pathologists will evaluate the utility of the Ion Torrent Genexus NGS system as a practical alternative for providing fast, accurate, and comprehensive molecular testing to inform cancer diagnosis. The turn around time and tissue requirements will be compared to single-gene testing or other NGS approaches. MAWD's team will focus their work on non-small cell lung and colorectal cancers, two cancer types where numerous targeted therapies are available that may improve patient outcomes. This study could provide substantial value in more effectively delivering on the promises of precision medicine for all patients, regardless of where they are treated.

"MAWD is proud to partner with Lilly and help advance molecular diagnostics for patients and physicians," said Ossama Tawfik, MD, PhD, MAWD pathologist and Principal Investigator. "This study underscores the need for increased awareness of broad molecular profiling use in the community setting and education on the potential for improved patient outcomes when the appropriate targeted therapy is used."

The trial will begin in Spring 2023 and is expected to determine the optimal testing approaches for patients serviced by MAWD.

About MAWD

MAWD Pathology one of the largest private, wholly physician-owned providers of pathology and laboratory services in the country. MAWD's team includes over 55 physicians caring for more than 250,000 patients across the Midwest each year. MAWD offers unmatched and diverse advanced subspecialty expertise and employs many of the region's recognized leaders in subspecialty pathology. MAWD is dedicated to delivering the highest quality care for its partners, clients, and the community and is proud to have served the region for over 50 years.

About Eli Lilly and Company

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.